These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 19442421)
1. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Feavers I; Knezevic I; Powell M; Griffiths E; Vaccine; 2009 Jun; 27(28):3681-8. PubMed ID: 19442421 [TBL] [Abstract][Full Text] [Related]
3. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; a PneumoCarr meeting report March 27-28, 2012, Geneva. Goldblatt D; Ramakrishnan M; O'Brien K Vaccine; 2013 Dec; 32(1):146-52. PubMed ID: 23933374 [TBL] [Abstract][Full Text] [Related]
4. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. Choo S; Zhang Q; Seymour L; Akhtar S; Finn A J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930 [TBL] [Abstract][Full Text] [Related]
5. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Zangeneh TT; Baracco G; Al-Tawfiq JA Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802 [TBL] [Abstract][Full Text] [Related]
6. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785 [TBL] [Abstract][Full Text] [Related]
7. Pneumococcal vaccines WHO position paper - 2012 - recommendations. WHO Publication Vaccine; 2012 Jul; 30(32):4717-8. PubMed ID: 22621828 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD; Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186 [TBL] [Abstract][Full Text] [Related]
10. Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Fritzell B; Fletcher MA Expert Rev Vaccines; 2011 Mar; 10(3):263-90. PubMed ID: 21434795 [TBL] [Abstract][Full Text] [Related]
11. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Jódar L; Butler J; Carlone G; Dagan R; Goldblatt D; Käyhty H; Klugman K; Plikaytis B; Siber G; Kohberger R; Chang I; Cherian T Vaccine; 2003 Jul; 21(23):3265-72. PubMed ID: 12804857 [TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model. Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627 [TBL] [Abstract][Full Text] [Related]
13. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Gruber WC; Scott DA; Emini EA Ann N Y Acad Sci; 2012 Aug; 1263():15-26. PubMed ID: 22830997 [TBL] [Abstract][Full Text] [Related]
14. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives. Bechini A; Boccalini S; Bonanni P Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829 [TBL] [Abstract][Full Text] [Related]
16. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Cherian T Vaccine; 2007 Sep; 25(36):6557-64. PubMed ID: 17681648 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449 [TBL] [Abstract][Full Text] [Related]
18. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458 [TBL] [Abstract][Full Text] [Related]
19. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451 [TBL] [Abstract][Full Text] [Related]
20. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Nuorti JP; Whitney CG; MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]